Stock Market Reviews

CRDF (Cardiff Oncology, Inc.) News

Get the latest news, insights, and market updates on CRDF (Cardiff Oncology, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
  SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti’s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025. Details of the presentation can be found below. Presenter: Mark Erlander, PhD (CEO) Date: 12/11/2025Time: 4:00 PM E
  Dec 8, 2025 - $CRDF
• Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025
  SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in chronic myelomonocytic leukemia (CMML) will be presented in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting. In this Phase 1 dose escalation trial (N=9), onvansertib
  Dec 8, 2025 - $CRDF
• Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference
  SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 37th Annual Healthcare Conference, which is taking place from December 2-4, 2025. Details of the presentation can be found below. Presenters: Mark Erlander, PhD (CEO) Date:
  Nov 24, 2025 - $CRDF
• KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsight
  The KRAS inhibitors market is expected to experience substantial growth, driven by rising cancer incidence, improved treatment access, and a robust pipeline including Olomorasib (Eli Lilly), MK-1084 (Merck/Taiho/Astex Pharmaceuticals), Divarasib (Roche), Daraxonrasib (Revoltuion Medicines), Onvansertib (Cardiff Oncology), ELI-002 (Elicio Therapeutics), and others across the 7MM. G12C is the most prevalent KRAS mutation in NSCLC, making it a key target of current therapies. Following the success
  Nov 12, 2025 - $CRDF
• Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
  – Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report an update from the Phase 2 CRDF-004 trial in Q1 2026 – – Cash and investments of $60.6 million as of September 30, 2025, projected runway into Q1 2027 – SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhib
  Nov 6, 2025 - $CRDF
• Cardiff Oncology: Q3 Earnings Snapshot
  SAN DIEGO (AP) — Cardiff Oncology, Inc. CRDF) on Thursday reported a loss of $11.3 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 17 cents.
  Nov 6, 2025 - $CRDF
• Cardiff Oncology to Participate in Two Upcoming Investor Conferences
  SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in November 2025. Guggenheim Securities 2nd Annual Healthcare Innovation ConferenceFormat: Fireside Chat and 1x1 MeetingsPresenters: Mark Erlander, PhD (CEO) Date: 11/11/2025Time: 9:30 AM ET Stifel 2025
  Nov 4, 2025 - $CRDF
• Cardiff Oncology to Participate in Three Upcoming Investor Conferences
  SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in the three upcoming investor conferences in September 2025. Details of the events can be found below. Wells Fargo 20th Annual Healthcare Conference Format: 1x1 Meetings Date: 09/05/2025Location: Encore Boston Harbor, Everett, MA Morgan S
  Aug 28, 2025 - $CRDF
• Cardiff Oncology Insiders Land Bargain With Gains Of US$244k
  Insiders who bought Cardiff Oncology, Inc. ( NASDAQ:CRDF ) stock lover the last 12 months are probably not as affected...
  Jul 30, 2025 - $CRDF
• Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
  - Appointed Dr. Roger Sidhu as Chief Medical Officer - - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Announced positive data from investigator-initiated trial of onvansertib in combination with paclitaxel in mTNBC at ASCO 2025 - - Cash and investments of $71.0 million as of June 30, 2025, projected runway into Q1 2027 - - Company to hold a conference call
  Jul 29, 2025 - $CRDF